PE20110220A1 - DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS - Google Patents

DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Info

Publication number
PE20110220A1
PE20110220A1 PE2011000113A PE2011000113A PE20110220A1 PE 20110220 A1 PE20110220 A1 PE 20110220A1 PE 2011000113 A PE2011000113 A PE 2011000113A PE 2011000113 A PE2011000113 A PE 2011000113A PE 20110220 A1 PE20110220 A1 PE 20110220A1
Authority
PE
Peru
Prior art keywords
amino
protein
propionamide
pyrrolidin
oxo
Prior art date
Application number
PE2011000113A
Other languages
English (en)
Inventor
Mark G Charest
Christine Hiu-Tung Chen
Zhuoliang Chen
Miao Dai
Feng He
Huangshu Lei
Ly Luu Pham
Sushil Kumar Sharma
Christopher Sean Straub
Rung-Ming David Wang
Fang Yang
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20110220A1 publication Critical patent/PE20110220A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS TALES COMO: (S)-N-((S)-1-CICLOHEXIL-2-{(S)-2-[6-(4-FLUORO-FENOXI)-2-METIL-PIRIMIDIN-4-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA, (S)-N-((S)-1-CICLOHEXIL-2-{(S)-2-[6-(4-FLUORO-BENZOIL)-2-METIL-PIRIMIDIN-4-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA, (S)-N-[(S)-1-CICLOHEXIL-2-((S)-2-{6-[(4-FLUORO-FENIL)-METIL-AMINO]-2-METIL-PIRIMIDIN-4-IL}-PIRROLIDIN-1-IL)-2-OXO-ETIL]-2-METIL-AMINO-PROPIONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE PROTEINAS DE APOPTOSIS (IAP) SIENDO UTILES EN EL TRATAMIENTO DE LINFOMA, LEUCEMIA, MIELOMA
PE2011000113A 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS PE20110220A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83500006P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PE20110220A1 true PE20110220A1 (es) 2011-04-11

Family

ID=38686647

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2011000113A PE20110220A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000112A PE20110218A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2007000978A PE20080951A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000114A PE20110224A1 (es) 2006-08-02 2007-07-26 PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
PE2011000111A PE20110217A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Family Applications After (4)

Application Number Title Priority Date Filing Date
PE2011000112A PE20110218A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2007000978A PE20080951A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000114A PE20110224A1 (es) 2006-08-02 2007-07-26 PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
PE2011000111A PE20110217A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Country Status (42)

Country Link
US (3) US8552003B2 (es)
EP (3) EP2537846B1 (es)
JP (1) JP4875749B2 (es)
KR (2) KR101245945B1 (es)
CN (2) CN102558165B (es)
AR (3) AR062159A1 (es)
AU (1) AU2007281230B2 (es)
BR (1) BRPI0714803B8 (es)
CA (1) CA2658525C (es)
CL (1) CL2007002234A1 (es)
CR (2) CR10567A (es)
CU (2) CU23866B1 (es)
DK (1) DK2051990T3 (es)
DO (1) DOP2013000084A (es)
EA (2) EA201401247A1 (es)
ES (2) ES2405947T3 (es)
GE (1) GEP20115251B (es)
GT (2) GT200900019A (es)
HK (2) HK1176613A1 (es)
HN (1) HN2009000214A (es)
HR (1) HRP20130373T1 (es)
IL (3) IL196596A (es)
JO (1) JO2848B1 (es)
MA (1) MA30652B1 (es)
ME (1) ME00585A (es)
MX (1) MX2009001212A (es)
MY (1) MY150460A (es)
NI (2) NI200900008A (es)
NO (1) NO342230B1 (es)
NZ (1) NZ574393A (es)
PA (1) PA8740901A1 (es)
PE (5) PE20110220A1 (es)
PL (1) PL2051990T3 (es)
PT (1) PT2051990E (es)
SI (1) SI2051990T1 (es)
SM (1) SMP200900013B (es)
SV (1) SV2009003160A (es)
TN (1) TN2009000034A1 (es)
TW (1) TWI408133B (es)
UA (1) UA95485C2 (es)
WO (1) WO2008016893A1 (es)
ZA (1) ZA200900371B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253614B1 (en) 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
EP1851200B1 (en) 2005-02-25 2014-01-15 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014252A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
NZ574311A (en) 2006-07-24 2011-12-22 Tetralogic Pharm Corp Dimeric iap antagonists
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2010507096A (ja) * 2006-10-19 2010-03-04 ノバルティス アーゲー 有機化合物
CA2670498A1 (en) * 2006-11-28 2008-06-05 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
WO2008085610A1 (en) * 2006-11-28 2008-07-17 Novartis Ag Use of iap inhibitors for the treatment of acute myeloid leukemia
JP2010513561A (ja) * 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド Ｉａｐのイミダゾピリジンインヒビター
CA2683392A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
ES2882855T3 (es) 2008-05-16 2021-12-02 Dana Farber Cancer Inst Inc Inmunomodulación por inhibidores de IAP
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011019782A1 (en) * 2009-08-11 2011-02-17 Novartis Ag Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
PE20170777A1 (es) * 2009-08-12 2017-07-04 Novartis Ag Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
HUE031420T2 (en) 2010-08-31 2017-07-28 Hanmi Science Co Ltd Quinoline or quinazoline derivatives having apoptosis-inducing effect on cells
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2731951B1 (en) 2011-07-13 2015-08-19 Novartis AG 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
CN104271566B (zh) * 2012-05-22 2017-05-31 霍夫曼-拉罗奇有限公司 取代的联吡啶胺及其用途
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
EP2991977B1 (en) 2013-05-01 2020-07-22 F.Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
AU2014301958B2 (en) 2013-06-25 2017-11-16 The Walter And Eliza Hall Institute Of Medical Research Method of treating intracellular infection
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PL3370768T3 (pl) 2015-11-03 2022-06-13 Janssen Biotech, Inc. Przeciwciała specyficznie wiążące pd-1 i ich zastosowania
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
WO2018178250A1 (en) 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Anticancer combination therapy
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JPWO2020027225A1 (ja) 2018-07-31 2021-11-11 ファイメクス株式会社 複素環化合物
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
CA3130706A1 (en) 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
EP3972651A2 (en) 2019-05-20 2022-03-30 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4006037A4 (en) 2019-07-31 2023-12-13 Fimecs, Inc. HETEROCYCLIC COMPOUND
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4034102A1 (en) 2019-09-25 2022-08-03 Debiopharm International SA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2021285068A1 (en) 2020-06-03 2023-01-19 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
KR20230138444A (ko) 2020-11-24 2023-10-05 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
AU2021388021A1 (en) 2020-11-24 2023-06-22 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
TW202404645A (zh) 2022-05-20 2024-02-01 瑞士商諾華公司 Met bcl-xl抑制劑抗體-藥物結合物及其使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
JPS59141547A (ja) * 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2004007529A2 (en) * 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
AU2003249920A1 (en) 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
US7067274B2 (en) * 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
JP2007523061A (ja) * 2004-01-16 2007-08-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｓｍａｃペプチドミメティクスおよびその使用法
SE527038C2 (sv) * 2004-02-26 2005-12-13 Ingenjoers N Per Oskar Persson Kassett och apparat för vätskefrysning
JP4674231B2 (ja) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
EP2253614B1 (en) * 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
US20060218632A1 (en) * 2005-03-28 2006-09-28 Cisco Technology, Inc.; Method and system for installing premise equipment
BRPI0719221A2 (pt) * 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
BRPI0720049A2 (pt) * 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap

Also Published As

Publication number Publication date
JP4875749B2 (ja) 2012-02-15
TN2009000034A1 (en) 2010-08-19
GT200900019A (es) 2010-06-01
ZA200900371B (en) 2009-12-30
MY150460A (en) 2014-01-30
PE20110224A1 (es) 2011-04-05
US20140004101A1 (en) 2014-01-02
IL231079A0 (en) 2014-03-31
EP2537850A1 (en) 2012-12-26
CN101511860B (zh) 2013-05-01
EP2051990A1 (en) 2009-04-29
BRPI0714803B1 (pt) 2021-03-09
MA30652B1 (fr) 2009-08-03
SMP200900013B (it) 2010-01-19
SI2051990T1 (sl) 2013-06-28
US20110065726A1 (en) 2011-03-17
CR20140555A (es) 2015-01-14
EP2537846B1 (en) 2015-09-16
US8546336B2 (en) 2013-10-01
CU24004B1 (es) 2014-06-27
NI200900081A (es) 2010-01-07
EP2051990B1 (en) 2013-02-06
HRP20130373T1 (en) 2013-05-31
WO2008016893A1 (en) 2008-02-07
TW200815399A (en) 2008-04-01
JP2009545613A (ja) 2009-12-24
ES2559042T3 (es) 2016-02-10
GEP20115251B (en) 2011-07-11
JO2848B1 (en) 2014-09-15
SV2009003160A (es) 2010-04-13
PE20110218A1 (es) 2011-04-01
AR112816A2 (es) 2019-12-18
EA021671B1 (ru) 2015-08-31
CN102558165B (zh) 2014-08-13
US8552003B2 (en) 2013-10-08
PE20080951A1 (es) 2008-09-11
EA201401247A1 (ru) 2015-07-30
UA95485C2 (uk) 2011-08-10
IL231079A (en) 2015-02-26
AR062159A1 (es) 2008-10-22
CU20110027A7 (es) 2011-12-28
CL2007002234A1 (es) 2008-06-13
HN2009000214A (es) 2011-10-11
AU2007281230B2 (en) 2011-09-08
SMAP200900013A (it) 2009-05-11
CU23866B1 (es) 2013-03-27
AU2007281230A1 (en) 2008-02-07
PA8740901A1 (es) 2009-04-23
IL236883A0 (en) 2015-03-31
US20130005663A1 (en) 2013-01-03
PL2051990T3 (pl) 2013-07-31
BRPI0714803A2 (pt) 2013-05-21
KR101087878B1 (ko) 2011-11-30
IL196596A (en) 2014-09-30
BRPI0714803B8 (pt) 2021-05-25
NO20090878L (no) 2009-04-27
ES2405947T3 (es) 2013-06-04
DK2051990T3 (da) 2013-05-13
EP2537846A1 (en) 2012-12-26
CA2658525C (en) 2013-02-19
NI200900008A (es) 2010-01-07
CN102558165A (zh) 2012-07-11
CR10567A (es) 2009-02-18
CN101511860A (zh) 2009-08-19
NZ574393A (en) 2012-03-30
HK1176613A1 (en) 2013-08-02
KR101245945B1 (ko) 2013-03-22
KR20110030667A (ko) 2011-03-23
MX2009001212A (es) 2009-02-11
TWI408133B (zh) 2013-09-11
KR20090038479A (ko) 2009-04-20
PT2051990E (pt) 2013-05-10
IL196596A0 (en) 2009-11-18
CA2658525A1 (en) 2008-02-07
DOP2013000084A (es) 2013-06-15
CU20090017A7 (es) 2011-03-21
PE20110217A1 (es) 2011-04-01
NO342230B1 (no) 2018-04-23
HK1127616A1 (en) 2009-10-02
ME00585B (me) 2011-12-20
EA200900227A1 (ru) 2009-08-28
GT200900019AA (es) 2015-11-24
AR110313A2 (es) 2019-03-13
ME00585A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
PE20110220A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20140849A1 (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
ECSP088759A (es) Composiciones farmacéuticas
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
PA8852901A1 (es) Inhibidores de proteina cinasa
BRPI0516027A (pt) compostos de sulfonamida
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
PE20150204A1 (es) Inhibidores de virus de hepatitis c
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
PE20140038A1 (es) Compuestos antivirales
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2009001044A1 (es) Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
TR201900071T4 (tr) Kontrollü Over Stimülasyonuna Yönelik Bileşim
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique
EA201201550A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз

Legal Events

Date Code Title Description
FC Refusal